目的 评估超敏肌钙蛋白I(high-Sesitivity troponin I,hs-cTnI)和N末端钠尿肽原(N terminal brain natriuretic peptide,NT-proBNP)对曲妥珠单抗致心脏毒性的预测价值。方法 收集117例医院接受蒽环类化疗药物序贯曲妥珠单抗治疗的乳腺癌患者的病例资料,在蒽环类化疗前(visit1)和曲妥珠单抗用药前(visit2)、曲妥珠单抗治疗开始的3个月(visit3)及随后每3个月1次进行全面的心脏检查和超声心动图评估心功能。在visit1、visit2和visit3检测hs-cTnI 和NT-proBNP的浓度,共随访15个月,发生心脏毒性事件为观察终点。根据曲妥珠单抗致心脏毒性的诊断指标,将患者分为心脏毒性组和非心脏毒性组。评价hs-cTnI 和NT-proBNP对曲妥珠单抗致心脏毒性的预测价值。结果 16例出现心脏毒性,心脏毒性组与非心脏毒性组的hs-cTnI水平在Visit2和Visit3,两组组间比较有统计学差异(P＜0.05),而NT-proBNP仅在曲妥珠单抗治疗治疗开始3个月两组间比较差异有统计学意义(P＜0.01)。以曲妥珠单抗治疗开始3个月的血清hs-cTnI和NT-proBNP浓度水平进行ROC曲线分析,可见hs-cTnI的AUC、特异度和敏感性都很高,且均优于 NT-proBNP ,故可认为,hs-cTnI是一个曲妥珠单抗致心脏毒性的预测生物标志物。
Abstract
Objective To evaluate the predictive value of cardiac troponin I (hs-cTnI) and N terminal brain natriuretic peptide (NT-proBNP) for cardiac toxicity induced by trastuzumab.Methods Clinical data on 117 patients with breast cancer treated in our hospital with anthracycline chemotherapy and sequential therapy of trastuzumab was collected. At baseline (visit1),before administration of anthracycline (visit2), 3 months into the administration of trastuzumab and paclitaxel(visit3), 6 months into the administration of trastuzumab,hs- cTnI and NT-proBNP levels were detected.The follow-up was 15 months. Echocardiography and questionnaires were used every three months(a total of 6 times).The patients were divided into two groups according to the diagnostic criteria of cardiac toxicity to assess the predictive value of hs-cTnI and NT-proBNP in the cardiac toxicity of trastuzumab.Results There were 16 cases of cardiac toxicity. and the difference in hs-cTnI levels at Visit2 and Visit3 was statistically significant between the cardiac toxicity group and the non cardiac toxicity group (P＜0.05), while levels of NT-proBNP were significantly different between the two groups only 3 months into trastuzumab treatment(P＜0.01). ROC curve analysis of the serum hs-cTnI and NT-proBNP concentrations suggested that the AUC, specificity and sensitivity of hs-cTnI were quite good.Conclusions hs-cTnI can serve as a predictive biomarker of cardiac toxicity s induced by trastuzumab.
关键词
超敏肌钙蛋白I /
N末端钠尿肽原 /
心脏毒性 /
预测价值
Key words
high-sensitivity troponin I /
N terminal brain natriuretic peptide /
cardiac toxicity /
predictive value
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Seidman A, Hudis C, Pierri M K,et al. Cardiac dysfunction in the trastuzumab clinical trials experience[J]. J Clin Oncol,2002,20(5):1215-1221.
[2] Yeh E T, Bickford C L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management[J]. J Am Coll Cardiol,2009,53(24):2237-2247.
[3] Slamon D, Eiermann W, Robert N,et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. N Engl J Med, 2011,365(14):1273-1283.
[4] Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. N Engl J Med, 2011,365:1273-1283.
[5] Guarneri V, Lenihan D J, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The MD anderson cancer center experience[J]. J Clin Oncol,2006, 24(25):4107-4115.
[6] Roth H J, Leithauser R M, Doppelmayr H,et al. Cardiospecificity of the 3rd generation cardiac troponin T assay during and after a 216 km ultra-endurance marathon run in Death Valley[J]. Clin Res Cardiol,2007,96(6):359-364.
[7] Kurz K, Voelker R, Zdunek D,et al. Effect of stress-induced reversible ischemia on serum concentrations of ischemiamodified albumin, natriuretic peptides and placental growth factor[J]. Clin Res Cardiol,2007,96(3):152-159.
[8] Mackey J R, Clemons M, Cté M A, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group[J]. Curr Oncol,2008,15:24-35.
[9] Seidman A, Hudis C, Pierri M K,et al. Cardiac dysfunction in the trastuzumab clinical trials experience[J]. J Clin Oncol,2002,20(5):1215-1221.
[10] 张瑞生.关注抗肿瘤治疗的心血管毒性[J].中国心血管杂志,2016,21(5):359-362.
[11] Hilmer S N, Cogger V C, Muller M,et al . The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. Drug Metab[J]. Dispos,2004,32(8):794-799.
[12] Slamon D J, Leyland-Jones B, Shak S,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl[J]. J Med,2001,344(11):783-792.
[13] Morris P G,Hudis C A. Anthracyclines and trastuzumab,getting to the heart of the matter: when getting to the heart is the matter[J].Breast Cancer Res Treat,2011,127(2):585-586.
[14] Ewer M S, Vooletich M T, Durand J B,et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment[J]. J Clin Oncol, 2005,23(31):7820-7826.
[15] 彭 毅,谭文勇.抗肿瘤治疗相关的心脏血管毒性:肿瘤心脏病学亟待跟进[J].临床与病理杂志,2015,35(3):433-443.
[16] 局 亮,尹 佳.评价药物早期心脏毒性的生物标记物研究进展[J].药物评价研究,2015,38(5):563-569.
[17] Sawaya H, Sebag I A, Plana J C,et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients[J].Am J Cardiol,2011,107(9):1375-1380.[18] Pichon M F, Cvitkovic F, Hacene K,et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography[J].In vivo,2005,19(3):567-576.
[19] Romano S, Fratini S, Ricevuto E,et al. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients[J]. Br J Cancer,2011,105(11):1663-1668.
[20] Sandri M T, Salvatici M, Cardinale D,et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction[J].Clin Chem,2013,51(8):14.
[21] Lipshultz S E, Scully R E, Lipsitz S R,et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial[J].Lancet Oncol,2010,11(10):950-961.
[22] Cardinale D, Colombo A, Lamantia G,et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy[J].J Am Coll Cardiol,2010,55(3):213-220.
[23] Cardinale D, Sandri M T, Colombo A,et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy[J].Circulation,2004,109(22):2749-2754.
PDF(772 KB)
